BACKGROUND:: HIV-1 drug resistance can be measured with phenotypic drug-resistance tests. However, the output of these tests, the resistance factor (RF), requires interpretation with respect to the in-vivo activity of the tested variant. Specifically, the dynamic range of the RF for each drug has to be divided into a suitable number of clinically meaningful intervals. METHODS:: We calculated a susceptible-to-intermediate and an intermediate-to-resistant cutoff per drug for RFs predicted by geno2pheno[resistance]. Probability densities for therapeutic success and failure were estimated from 10,444 treatment episodes. The density estimation procedure corrects for the activity of the backbone drug compounds and for therapy failure without drug resistance. For estimating the probability of therapeutic success given an RF, we fit a sigmoid function. The cutoffs are given by the roots of the third derivative of the sigmoid function. RESULTS:: For performance assessment, we used geno2pheno[resistance] RF predictions and the cutoffs for predicting therapeutic success in two independent sets of therapy episodes. HIVdb was used for performance comparison. On one test set (n=807), our cutoffs and HIVdb performed equally well (ROC-AUC: 0.68). On the other test set (n=917), our cutoffs (ROC-AUC: 0.63) and HIVdb (ROC-AUC: 0.65) performed comparatively well. CONCLUSIONS:: Our method can be used for calculating clinically relevant cutoffs for (predicted) RFs. The method corrects for the activity of the backbone drug compounds and for therapy failure without drug resistance. Our method’s performance is comparable to that of HIVdb. RF cutoffs for the latest version of geno2pheno[resistance] have been estimated with this method.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Pironti, A., Walter, H., Pfeifer, N., Knops, E., Lübke, N., Büch, J., Di Giambenedetto, S., Kaiser, R., Lengauer, T., Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data, <<JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES>>, 2017; 2016 (n/a): 1-N/A. [doi:10.1097/QAI.0000000000001198] [http://hdl.handle.net/10807/94840]

Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data

Joachim; Di Giambenedetto;
2016

Abstract

BACKGROUND:: HIV-1 drug resistance can be measured with phenotypic drug-resistance tests. However, the output of these tests, the resistance factor (RF), requires interpretation with respect to the in-vivo activity of the tested variant. Specifically, the dynamic range of the RF for each drug has to be divided into a suitable number of clinically meaningful intervals. METHODS:: We calculated a susceptible-to-intermediate and an intermediate-to-resistant cutoff per drug for RFs predicted by geno2pheno[resistance]. Probability densities for therapeutic success and failure were estimated from 10,444 treatment episodes. The density estimation procedure corrects for the activity of the backbone drug compounds and for therapy failure without drug resistance. For estimating the probability of therapeutic success given an RF, we fit a sigmoid function. The cutoffs are given by the roots of the third derivative of the sigmoid function. RESULTS:: For performance assessment, we used geno2pheno[resistance] RF predictions and the cutoffs for predicting therapeutic success in two independent sets of therapy episodes. HIVdb was used for performance comparison. On one test set (n=807), our cutoffs and HIVdb performed equally well (ROC-AUC: 0.68). On the other test set (n=917), our cutoffs (ROC-AUC: 0.63) and HIVdb (ROC-AUC: 0.65) performed comparatively well. CONCLUSIONS:: Our method can be used for calculating clinically relevant cutoffs for (predicted) RFs. The method corrects for the activity of the backbone drug compounds and for therapy failure without drug resistance. Our method’s performance is comparable to that of HIVdb. RF cutoffs for the latest version of geno2pheno[resistance] have been estimated with this method.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Inglese
Pironti, A., Walter, H., Pfeifer, N., Knops, E., Lübke, N., Büch, J., Di Giambenedetto, S., Kaiser, R., Lengauer, T., Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data, <<JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES>>, 2017; 2016 (n/a): 1-N/A. [doi:10.1097/QAI.0000000000001198] [http://hdl.handle.net/10807/94840]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/94840
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact